Protocol Ledger

NCT05749822 · Phase II/III · RECRUITING

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Interventional Phase II/III clinical trial protocol NCT05749822 sponsored by Xijing Hospital of Digestive Diseases in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-17 Enrollment: 104 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05749822
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)104 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05749822
Protocol FieldVerified Registry Value
NCT IdentifierNCT05749822
Consolidated Lead SponsorXijing Hospital of Digestive Diseases
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment104 participants (ESTIMATED)
Registered Start Date2023-02-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI